Shopping Cart
- Remove All
- Your shopping cart is currently empty
BMS-248360 is a potent, orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptors, respectively. BMS-248360 demonstrates hypertensive effects[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,720 | 10-14 weeks | |
50 mg | $3,580 | 10-14 weeks | |
100 mg | $4,900 | 10-14 weeks |
Description | BMS-248360 is a potent, orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptors, respectively. BMS-248360 demonstrates hypertensive effects[1]. |
Targets&IC50 | ETA receptor (rat):1.9 nM, AT1 (rat):6.0 nM(ki), ETA receptor (human):1.9 nM(ki), AT1 (human):(ki)10 nM |
In vitro | BMS-248360 shows no activity against AT2 and ETB receptor subtypes and it also shows activity against rat AT1 and rat ETA receptor, with Kis of 6.0 nM and 1.9 nM, respectively[1]. |
In vivo | BMS-248360 is orally bioavailable in rats (%F=38) with excellent oral exposure (Cmax=3.1 μM) and a reasonable elimination profile (T1/2=5.5 hours)[1]. At dosages of 30 and 100 μmol/kg (p.o.), it effectively blocks the hypertensive effects of intravenously administered AII[1]. |
Molecular Weight | 659.84 |
Formula | C36H45N5O5S |
Cas No. | 254737-87-6 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.